200 related articles for article (PubMed ID: 37332068)
21. SUV
Hartrampf PE; Hüttmann T; Seitz AK; Kübler H; Serfling SE; Schlötelburg W; Michalski K; Rowe SP; Pomper MG; Buck AK; Eberlein U; Werner RA
Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3465-3474. PubMed ID: 37272956
[TBL] [Abstract][Full Text] [Related]
22. The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol.
Pouliot F; Beauregard JM; Saad F; Trudel D; Richard PO; Turcotte É; Rousseau É; Probst S; Kassouf W; Anidjar M; Camirand Lemyre F; Bouvet GF; Neveu B; Tétu A; Guérin B
BJU Int; 2022 Sep; 130(3):314-322. PubMed ID: 34674367
[TBL] [Abstract][Full Text] [Related]
23. Initial Experience with Volumetric
Schmuck S; von Klot CA; Henkenberens C; Sohns JM; Christiansen H; Wester HJ; Ross TL; Bengel FM; Derlin T
J Nucl Med; 2017 Dec; 58(12):1962-1968. PubMed ID: 28522740
[TBL] [Abstract][Full Text] [Related]
24. Prostate-Specific Membrane Antigen Expression on PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Observational Study.
Calderoni L; Maietti E; Farolfi A; Mei R; Louie KS; Groaning M; Fanti S
J Nucl Med; 2023 Jun; 64(6):910-917. PubMed ID: 36635087
[TBL] [Abstract][Full Text] [Related]
25. Concept proposal for a six-tier integrated dual tracer PET-CT (68Ga-PSMA and FDG) image scoring system ('Pro-PET' score) and examining its potential implications in metastatic castration-resistant prostate carcinoma theranostics and prognosis.
Adnan A; Basu S
Nucl Med Commun; 2021 May; 42(5):566-574. PubMed ID: 33560718
[TBL] [Abstract][Full Text] [Related]
26. Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with
Wibmer AG; Morris MJ; Gonen M; Zheng J; Hricak H; Larson S; Scher HI; Vargas HA
J Nucl Med; 2021 Aug; 62(8):1050-1056. PubMed ID: 33419944
[TBL] [Abstract][Full Text] [Related]
27. Comparison of PET/CT-based eligibility according to VISION and TheraP trial criteria in end-stage prostate cancer patients undergoing radioligand therapy.
Michalski K; Kosmala A; Werner RA; Serfling SE; Seitz AK; Lapa C; Buck AK; Hartrampf PE
Ann Nucl Med; 2024 Feb; 38(2):87-95. PubMed ID: 37891376
[TBL] [Abstract][Full Text] [Related]
28. The role of Ga
Erdogan M; Sengul SS; Cetin B; Avcı M; Yagci S; Ozkoç I; Barikan DE; Yildiz M
Ann Nucl Med; 2022 Jun; 36(6):562-569. PubMed ID: 35397091
[TBL] [Abstract][Full Text] [Related]
29. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID;
BJU Int; 2021 Nov; 128(5):642-651. PubMed ID: 34028967
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma.
Kim JW; Oh JS; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY
Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1353-61. PubMed ID: 26067088
[TBL] [Abstract][Full Text] [Related]
31. The Impact of PSMA PET-Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy.
Karimzadeh A; Heck M; Tauber R; Solaris E; Nekolla S; Knorr K; Haller B; D'Alessandria C; Weber WA; Eiber M; Rauscher I
J Nucl Med; 2023 Aug; 64(8):1252-1258. PubMed ID: 37290796
[TBL] [Abstract][Full Text] [Related]
32. Predictive factors of tumor sink effect: Insights from
Tuncel M; Telli T; Tuncalı MÇ; Karabulut E
Ann Nucl Med; 2021 May; 35(5):529-539. PubMed ID: 33586096
[TBL] [Abstract][Full Text] [Related]
33. A prospective study on the early evaluation of response to androgen receptor-targeted agents with
Mollica V; Marchetti A; Fraccascia N; Nanni C; Tabacchi E; Malizia C; Argalia G; Rosellini M; Tassinari E; Paccapelo A; Fanti S; Massari F
ESMO Open; 2024 May; 9(5):103448. PubMed ID: 38718704
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Value of Metabolic and Volumetric Parameters of Preoperative FDG-PET/CT in Patients With Resectable Pancreatic Cancer.
Im HJ; Oo S; Jung W; Jang JY; Kim SW; Cheon GJ; Kang KW; Chung JK; Kim EE; Lee DS
Medicine (Baltimore); 2016 May; 95(19):e3686. PubMed ID: 27175707
[TBL] [Abstract][Full Text] [Related]
35. Pretreatment quantitative
Gencturk M; Ozturk K; Koksel Y; Li F; Cayci Z
Clin Imaging; 2019; 53():17-24. PubMed ID: 30308429
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of primary tumor and lymph node volumetric metabolic parameters at pre-treatment F-18 FDG PET/CT in nasopharyngeal carcinoma.
Demirel BB; Gülbahar Ateş S; Atasever Akkaş E; Göksel F; Uçmak G
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2023; 42(6):367-373. PubMed ID: 37391092
[TBL] [Abstract][Full Text] [Related]
38. Lymph node standardized uptake values at pre-treatment
Jeong Y; Baek S; Park JW; Joo JH; Kim JS; Lee SW
Br J Radiol; 2017 Mar; 90(1071):20160239. PubMed ID: 28008776
[TBL] [Abstract][Full Text] [Related]
39. Metabolic parameters of [
Markus M; Sartor H; Bjurberg M; Trägårdh E
Acta Oncol; 2023 Feb; 62(2):180-188. PubMed ID: 36815676
[TBL] [Abstract][Full Text] [Related]
40. Combined
Suman S; Parghane RV; Joshi A; Prabhash K; Talole S; Basu S
Prostate; 2021 Nov; 81(15):1225-1234. PubMed ID: 34469602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
